Cystic Fibrosis Weekly Update

Contents:

Eloxx Presents More Positive Preclinical Data for ELX-02, Potential CF Treatment

Mar 29, 2019 07:00 am | Ana Pena

Eloxx Pharmaceuticals presented new positive preclinical data for ELX-02, its lead treatment candidate for cystic fibrosis (CF), demonstrating that the therapy increases the levels of CFTR protein and its correct placement at the cell’s surface in patient-derived organoids. Findings were presented by Shira Landskroner-Eiger, PhD, Eloxx’s principal scientist at the 2019 European Cystic Fibrosis Society (ECFS) […]
The post Eloxx Presents More Positive Preclinical Data for ELX-02, Potential CF Treatmentappeared first on Cystic Fibrosis News Today.

My Body Is Not Always a Temple: Work-life Balance with CF

Mar 28, 2019 09:00 am | Elly Aylwin-Foster

Many young professionals burn the candle at both ends, especially when the temptation to fit into a big city’s lifestyle lurks. Somehow, they continue to function as productive humans — for the most part. But a person with cystic fibrosis (CF) and those in their trusted circle know that holding down a job and taking […]
The post My Body Is Not Always a Temple: Work-life Balance with CF appeared first on Cystic Fibrosis News Today.

Costs for CF Therapies Could Double in 2019, According to Pharmacy Benefit Manager

Mar 28, 2019 07:00 am | Santiago Gisler

Costs for approved cystic fibrosis (CF) treatments and new approvals — including therapies extended to more age groups or targeting new mutations — could double in price, according to pharmacy benefit manager (PBM) Prime Therapeutics. The cost increases could result in higher premiums for Prime members. According to the company, the forecast comes as a […]
The post Costs for CF Therapies Could Double in 2019, According to Pharmacy Benefit Managerappeared first on Cystic Fibrosis News Today.